宫颈原位腺癌保守治疗后采用高危人乳头瘤病毒检测和细胞学检查的最佳随访策略
该研究基于荷兰全国病理数据库1990—2021年保守治疗宫颈原位腺癌的回顾性队列,分析3411例患者,按6、12、18、24个月的高危人乳头瘤病毒检测和/或细胞学结果分层,评估5年复发原位腺癌、宫颈上皮内瘤变3级或宫颈癌的累积发生率。结论认为,2年内连续2次高危人乳头瘤病毒阴性或正常联合检测后复发风险低,似乎可以转回国家宫颈癌筛查计划。
要点
- 治疗后6个月单次高危人乳头瘤病毒阴性者5年复发风险2.3%,阳性者20.1%。
- 治疗后6个月细胞学正常者5年复发风险3%,低级别5.9%,高级别52.1%。
- 6和12个月连续高危人乳头瘤病毒阴性者5年累积复发风险0.6%。
核心结论
- 保守治疗宫颈原位腺癌后2年内连续2次高危人乳头瘤病毒阴性或正常联合检测,复发原位腺癌、宫颈上皮内瘤变3级或宫颈癌的风险低,似乎可以转回国家宫颈癌筛查计划(如适用)。
研究设计与样本
- 全国性回顾性队列,纳入荷兰全国病理数据库(Palga)1990—2021年保守治疗宫颈原位腺癌患者,随访数据来自Central Bureau for Genealogy。
- 共3411例患者符合分析条件,3312/3411例(97.1%)有随访前5年高危人乳头瘤病毒检测和/或细胞学结果。
主要发现
- 治疗后6个月单次高危人乳头瘤病毒阴性者5年复发原位腺癌、宫颈上皮内瘤变3级或宫颈癌累积发生率为2.3%(95%CI 0.8-3.7),阳性者为20.1%(95%CI 14.2-25.5)。
- 治疗后6个月细胞学正常者5年复发风险为3%(95%CI 2.2-3.8),低级别细胞学者为5.9%(95%CI 3.4-8.4),高级别细胞学者为52.1%(95%CI 42.7-59.9)。
- 6和12个月、6和18个月、6和24个月连续高危人乳头瘤病毒阴性者5年累积复发风险分别为0.6%(95%CI 0-1.8)、1.1%(95%CI 0-3.4)、0%(95%CI不适用)。
- 6和12个月、6和18个月、6和24个月连续正常联合检测(高危人乳头瘤病毒阴性且细胞学正常或低级别)者5年累积复发风险分别为0.6%(95%CI 0-1.8)、1.2%(95%CI 0-3.5)、0%(95%CI不适用)。
临床怎么用
- 作者认为,保守治疗宫颈原位腺癌后2年内连续2次高危人乳头瘤病毒阴性或正常联合检测后,复发风险低,似乎可以转回国家宫颈癌筛查计划(如适用)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: After treatment for cervical adenocarcinoma in situ, patients remain a risk for recurrent adenocarcinoma in situ, cervical intraepithelial grade 3, or cervical cancer. OBJECTIVE: This study aimed to determine the optimal follow-up strategy for high-risk human papillomavirus and cytology testing in conservatively treated patients with adenocarcinoma in situ. STUDY DESIGN: Patients were selected from a nationwide, retrospective cohort that included pathology reports from the Dutch Nationwide Pathology Databank (Palga) and survival data from the Central Bureau for Genealogy for patients conservatively treated for adenocarcinoma in situ between 1990 and 2021. The main outcome was the 5-year cumulative incidence of recurrent adenocarcinoma in situ, cervical intraepithelial neoplasia grade 3, or cervical cancer stratified by single and consecutive human papillomavirus test and/or cytology results at 6, 12, 18, and 24 months. RESULTS: A total of 3411 patients were eligible for analysis. High-risk human papillomavirus test and/or cytology results in the first 5 years of follow-up were available in 3312 of 3411 patients (97.1%), including 5207 high-risk human papillomavirus test results of 1928 patients and 13,369 cytology results of 3306 patients. Up to 5 years after a single high-risk human papillomavirus test at 6 months after treatment, the incidence of recurrent adenocarcinoma in situ, cervical intraepithelial neoplasia grade 3, or cervical cancer was lower among high-risk human papillomavirus-negative patients (2.3%; 95% confidence interval, 0.8-3.7) compared with high-risk human papillomavirus-positive patients (20.1%; 95% confidence interval, 14.2-25.5). Patients with normal cytology results 6 months after treatment for adenocarcinoma in situ had a lower incidence of recurrent adenocarcinoma in situ, cervical intraepithelial neoplasia grade 3, or cervical cancer (3%; 95% confidence interval, 2.2-3.8) compared with patients with low-grade (5.9%; 95% confidence interval, 3.4-8.4) or high-grade cytology (52.1%; 95% confidence interval, 42.7-59.9). The 5-year cumulative incidence of recurrent adenocarcinoma in situ, cervical intraepithelial neoplasia grade 3, or cervical cancer among patients testing negative for high-risk human papillomavirus consecutively at 6 and 12, 6 and 18, and 6 and 24 months was 0.6% (95% confidence interval, 0-1.8), 1.1% (95% confidence interval, 0-3.4), and 0% (95% confidence interval not applicable), respectively. Similarly, for patients with consecutive normal cotest results (high-risk human papillomavirus-negative with normal or low-grade cytology) at 6 and 12, 6 and 18, and 6 and 24 months, the 5-year cumulative incidence of recurrent adenocarcinoma in situ, cervical intraepithelial neoplasia grade 3, or cervical cancer was 0.6% (95% confidence interval, 0-1.8), 1.2% (95% confidence interval, 0-3.5), and 0% (95% confidence interval not applicable), respectively. CONCLUSION: After 2 consecutive negative high-risk human papillomavirus or normal cotests within 2 years after conservative adenocarcinoma in situ treatment, the risk of recurrent adenocarcinoma in situ, cervical intraepithelial neoplasia grade 3, or cervical cancer is low, and it seems acceptable to refer patients back to the national cervical cancer screening program, if applicable.
引用
- Schaafsma M, Schuurman TN, van Maurik IS, et al. Optimal follow-up strategy using high-risk human papillomavirus testing and cytology after conservative treatment for cervical adenocarcinoma in situ. Am J Obstet Gynecol. 2025. PMID: 40482946. doi:10.1016/j.ajog.2025.05.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。